USTR review could mean tough times ahead
Withdrawal of the GSP scheme could hit the industry quite hard
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
Beyond the budget
Pharma companies are likely to spend higher on R&D but without the high returns
Will a toothless drug price watchdog be good or bad for business?
A quid pro quo, of an easing drug price control, in exchange for increased investments in manufacturing, backward integration…
Out with the old, on with the new
Pfizer's loss will be the gain of numerous pharma companies and CROs as they look to hire from this talent pool The new year…
Where is the patient in the e-pharmacy debate?
e-pharmacies cannot be considered a mere extension of the e-commerce boom, simply because the patient cannot tell the difference…
Will quality trip or lift us up in 2019?
If 2018 was defined by Ayushman Bharat, what will define 2019? As we wind up one year and gear up for the next, I wonder how CEOs…
Achieving UNAIDS’ 90-90-90: A tall task
Merely having an HIV/AIDS Act or NACO’s strategic plan will not help because as NACO’s Director Alok Saxena puts it, human…
Dipping rupee to boost FY19 pharma revenues but …
Smart companies will focus on discovering avenues which lead to long-term sustainable growth
Competition watch dog raps pharma sector for non-competitive market moves
While the Competition Commission of India (CCI) note appreciates 'legitimate public policy objectives', it tries to determine the…
The pharma play in Ayushman Bharat
With saturation in export markets and rising regulatory constraints, will we see a refocus on the domestic market, prodded by…
India’s FDC saga and other stories
Framing regulations is one thing, interpreting and implementing them quite another saga, allowing repeat offenders like Biomed to…
Putting the bite into our laws
The recent faulty hip implant episode proves that our laws have not evolved as fast as medical technology
Revitalising pharmacy education
While there are good intentions, it is the implementation which threatens the viability of initiatives like the Pharm D course…
Playing for global stakes
Most bigger pharma companies have moved to the next level of exports: the trade of intellectual property, in the form of clinical…
Will indigenisation, innovation and information lead to true independence?
In my Editors Note in last year's Independence Day special issue, I had asked: as we mark our 71st Independence Day this August…
Acing the value chain
It is ironical that a Chinese movie seems to have done what India's policy makers have been trying to do for many years: get China…
Cracking down on fake medicines
One of the important proposals considered during the 79th Drug Technical Advisory Board (DTAB) meeting held on May 16 was the…
Halol haze lifts, finally
It’s time to count the learnings from Halol, both internally for Sun Pharma as well as for India Pharma Inc
Putting all patients first
In a speech on May 12, US President Donald Trump put one of his most populist election promises — to make medicines more…
Diving deeper into pharma GMP
For the past two years, the May 16-31 edition of Express Pharma has been a GMP Special issue, highlighting topics crucial to…